Kliff believes that Byetta could "easily capture" 10% of the market within the first year.
FORBES: Magazine Article
Click here for more information and analysis from David Kliff or to subscribe to Diabetic Investor.
FORBES: Setting Up For A Diabetes Squeeze
For more on David Kliff's recommendation of Amylin, click here to watch a video.
FORBES: Amylin Pharmaceuticals: Diabetes Relief
应用推荐
模块上移
模块下移
不移动